4/1
07:45 am
cgtx
Cognition Therapeutics Presents Results at AD/PD 2025 Showing Impact of Zervimesine (CT1812) on Alzheimer's Disease Processes [Yahoo! Finance]
Medium
Report
Cognition Therapeutics Presents Results at AD/PD 2025 Showing Impact of Zervimesine (CT1812) on Alzheimer's Disease Processes [Yahoo! Finance]
4/1
07:30 am
cgtx
Cognition Therapeutics Presents Results at AD/PD 2025 Showing Impact of Zervimesine (CT1812) on Alzheimer’s Disease Processes
High
Report
Cognition Therapeutics Presents Results at AD/PD 2025 Showing Impact of Zervimesine (CT1812) on Alzheimer’s Disease Processes
3/25
09:07 am
cgtx
Cognition Therapeutics to Report Biomarker Results from Phase 2 SHINE Study in Mild-to-Moderate Alzheimer's Disease in Podium Presentation at AD/PD 2025 [Yahoo! Finance]
Medium
Report
Cognition Therapeutics to Report Biomarker Results from Phase 2 SHINE Study in Mild-to-Moderate Alzheimer's Disease in Podium Presentation at AD/PD 2025 [Yahoo! Finance]
3/25
07:30 am
cgtx
Cognition Therapeutics to Report Biomarker Results from Phase 2 SHINE Study in Mild-to-Moderate Alzheimer’s Disease in Podium Presentation at AD/PD 2025
Medium
Report
Cognition Therapeutics to Report Biomarker Results from Phase 2 SHINE Study in Mild-to-Moderate Alzheimer’s Disease in Podium Presentation at AD/PD 2025
3/24
08:09 am
cgtx
Cognition Therapeutics, Inc. (NASDAQ: CGTX) had its price target lowered by analysts at HC Wainwright from $6.00 to $5.00. They now have a "buy" rating on the stock.
Medium
Report
Cognition Therapeutics, Inc. (NASDAQ: CGTX) had its price target lowered by analysts at HC Wainwright from $6.00 to $5.00. They now have a "buy" rating on the stock.
3/21
08:09 am
cgtx
Cognition Therapeutics, Inc. (NASDAQ: CGTX) had its price target lowered by analysts at Chardan Capital from $11.00 to $8.00. They now have a "buy" rating on the stock.
Medium
Report
Cognition Therapeutics, Inc. (NASDAQ: CGTX) had its price target lowered by analysts at Chardan Capital from $11.00 to $8.00. They now have a "buy" rating on the stock.
3/20
07:07 am
cgtx
Cognition Therapeutics Reports Year End 2024 Financial Results and Provides Business Update [Yahoo! Finance]
Medium
Report
Cognition Therapeutics Reports Year End 2024 Financial Results and Provides Business Update [Yahoo! Finance]
3/20
07:00 am
cgtx
Cognition Therapeutics Reports Year End 2024 Financial Results and Provides Business Update
Medium
Report
Cognition Therapeutics Reports Year End 2024 Financial Results and Provides Business Update
3/14
08:35 am
cgtx
Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing
Low
Report
Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing
3/13
04:05 pm
cgtx
Cognition Therapeutics to Report Fourth Quarter and Full Year 2024 Results
Medium
Report
Cognition Therapeutics to Report Fourth Quarter and Full Year 2024 Results
3/12
08:07 pm
cgtx
Cognition Therapeutics Granted Extension to Meet Nasdaq Minimum Bid Price Requirement for Continued Exchange Listing [Yahoo! Finance]
Medium
Report
Cognition Therapeutics Granted Extension to Meet Nasdaq Minimum Bid Price Requirement for Continued Exchange Listing [Yahoo! Finance]
3/12
04:05 pm
cgtx
Cognition Therapeutics Granted Extension to Meet Nasdaq Minimum Bid Price Requirement for Continued Exchange Listing
Medium
Report
Cognition Therapeutics Granted Extension to Meet Nasdaq Minimum Bid Price Requirement for Continued Exchange Listing
3/12
01:12 pm
cgtx
Life Sciences Investor Forum Agenda Announced for March 13th
Low
Report
Life Sciences Investor Forum Agenda Announced for March 13th
3/10
07:38 am
cgtx
Cognition Therapeutics to Present at Life Sciences Virtual Investor Conference [Yahoo! Finance]
Medium
Report
Cognition Therapeutics to Present at Life Sciences Virtual Investor Conference [Yahoo! Finance]
3/10
07:30 am
cgtx
Cognition Therapeutics to Present at Life Sciences Virtual Investor Conference
Medium
Report
Cognition Therapeutics to Present at Life Sciences Virtual Investor Conference
2/27
07:30 am
cgtx
Cognition Therapeutics Publishes Research Supporting the Potential of Zervimesine in Dry AMD
Medium
Report
Cognition Therapeutics Publishes Research Supporting the Potential of Zervimesine in Dry AMD
2/26
06:18 pm
cgtx
Cognition Therapeutics, Inc. (NASDAQ: CGTX) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $11.00 price target on the stock.
Low
Report
Cognition Therapeutics, Inc. (NASDAQ: CGTX) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $11.00 price target on the stock.
2/26
07:00 am
cgtx
Cognition Therapeutics Successfully Passes Pre-defined Futility Analysis of Phase 2 Study of Oral Zervimesine (CT1812) in Geographic Atrophy
Medium
Report
Cognition Therapeutics Successfully Passes Pre-defined Futility Analysis of Phase 2 Study of Oral Zervimesine (CT1812) in Geographic Atrophy
2/25
07:40 am
cgtx
Cognition Therapeutics' VP of Research Co-hosting Precision Medicine Workshop at the Neuroimmunology Drug Development Summit [Yahoo! Finance]
Medium
Report
Cognition Therapeutics' VP of Research Co-hosting Precision Medicine Workshop at the Neuroimmunology Drug Development Summit [Yahoo! Finance]
2/25
07:30 am
cgtx
Cognition Therapeutics’ VP of Research Co-hosting Precision Medicine Workshop at the Neuroimmunology Drug Development Summit
Medium
Report
Cognition Therapeutics’ VP of Research Co-hosting Precision Medicine Workshop at the Neuroimmunology Drug Development Summit
2/20
07:30 am
cgtx
Cognition Therapeutics Announces Publication of Commercial Manufacturing Process for Lead Alzheimer’s Candidate, Zervimesine (CT1812)
Medium
Report
Cognition Therapeutics Announces Publication of Commercial Manufacturing Process for Lead Alzheimer’s Candidate, Zervimesine (CT1812)
1/30
08:36 am
cgtx
Cognition's Positive Phase 2 ‘SHIMMER' Study of Zervimesine (CT1812) in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at ILBDC [Yahoo! Finance]
Low
Report
Cognition's Positive Phase 2 ‘SHIMMER' Study of Zervimesine (CT1812) in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at ILBDC [Yahoo! Finance]
1/30
07:30 am
cgtx
Cognition’s Positive Phase 2 ‘SHIMMER’ Study of Zervimesine (CT1812) in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at ILBDC
Low
Report
Cognition’s Positive Phase 2 ‘SHIMMER’ Study of Zervimesine (CT1812) in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at ILBDC
1/28
05:57 am
cgtx
Cognition Therapeutics, Inc. (NASDAQ: CGTX) was upgraded by analysts at Brookline Capital Management to a "strong-buy" rating.
Medium
Report
Cognition Therapeutics, Inc. (NASDAQ: CGTX) was upgraded by analysts at Brookline Capital Management to a "strong-buy" rating.
1/8
04:14 pm
cgtx
Cognition Therapeutics CEO Participating in Longwood and Sachs Conferences
Medium
Report
Cognition Therapeutics CEO Participating in Longwood and Sachs Conferences